Lyra Therapeutics, Inc.
LYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $12,084 | $415,590 | $671,975 |
| - Cash | $22,055 | $29,784 | $31,735 | $40,577 |
| + Debt | $26,695 | $32,478 | $33,356 | $34,380 |
| Enterprise Value | – | $14,778 | $417,211 | $665,778 |
| Revenue | $25 | $183 | $183 | $209 |
| % Growth | -86.3% | 0% | -12.4% | – |
| Gross Profit | -$75 | -$17 | $183 | $209 |
| % Margin | -300% | -9.3% | 100% | 100% |
| EBITDA | -$5,881 | -$7,235 | -$7,828 | -$9,615 |
| % Margin | -23,524% | -3,953.6% | -4,277.6% | -4,600.5% |
| Net Income | -$5,984 | -$7,437 | -$8,547 | -$10,979 |
| % Margin | -23,936% | -4,063.9% | -4,670.5% | -5,253.1% |
| EPS Diluted | -3.38 | -5.51 | -0.13 | -0.17 |
| % Growth | 38.7% | -4,138.5% | 23.5% | – |
| Operating Cash Flow | -$7,361 | -$6,590 | -$8,842 | -$11,352 |
| Capital Expenditures | $0 | -$20 | $0 | $58 |
| Free Cash Flow | -$7,361 | -$6,610 | -$8,842 | -$11,294 |